Adverse cardiovascular outcomes and mortality risks were higher among patients with type 1 diabetes relative to type 2 ...

Topline results were announced from a phase 3 head-to-head study comparing orforglipron with oral semaglutide in adults with ...

(HealthDay News) — Progress in cancer research, including approval of 20 new anticancer therapeutics in the past year, is ...

The rate of death from second primary malignancies has increased among older prostate cancer survivors in the US, data suggest.

(HealthDay News) — In children and adolescents with type 2 diabetes (T2D) or obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve glycemic, weight, and cardiometabolic outcomes, ...

(HealthDay News) — For persons aged 65 years and younger, nonatherothrombotic causes comprise a considerable burden of acute myocardial infarction (MI), according to a study published in the Sept. 23 ...

Greatest risk for mortality seen with high blood pressure, glucose intolerance, and low high-density lipoprotein cholesterol.

New opioid prescribing was stable for patients with metastatic cancer with pain and declined for those reporting no pain.

The FDA has approved Bosaya and Aukelso, biosimilars to Prolia (denosumab) and Xgeva (denosumab), respectively.

Children undergoing kidney transplantation are susceptible to serious complications if exposed to Epstein-Barr virus infection.

Cisplatin-based neoadjuvant chemotherapy typically improves outcomes for patients with muscle-invasive bladder cancer, but not all groups benefit.